Susan Axelby, 66, has reached a settlement with Allergan Ltd following her diagnosis with Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare but severe form of non-Hodgkin’s lymphoma linked to the company’s now-discontinued breast implants.
Axelby underwent double mastectomies in 1999 due to a high familial risk of breast cancer. Subsequently, she received breast implants manufactured by Allergan. Over the years, Axelby experienced persistent issues with the implants, including notable swelling and pain around the right side.
In 2018, Axelby was diagnosed with BIA-ALCL, a condition that has been specifically associated with Allergan breast implants. The same year, the implants were suspended from the global market, and following a recall in 2019, they are no longer available in the UK.
In November 2023, Axelby settled her claim with Allergan, though the company did not admit liability. Despite the financial settlement, Axelby emphasized the importance of raising awareness about the risks associated with these implants.
“My diagnosis with BIA-ALCL was a nightmare,” Axelby said. “The impact on my life has been significant. I pursued legal action against Allergan to ensure accountability and to highlight the dangers associated with these implants. Experts have indicated that some of these implants can cause cancer, and it is vital for other women to be informed of these risks.”
Sarah Moore, a partner in the international claims department at the law firm Leigh Day, which represented Axelby, expressed relief at achieving a settlement but warned that risks remain. “I am pleased we secured this settlement for Susan and hope it offers her some closure regarding her challenging experience with Allergan implants,” Moore stated. “Women with Allergan breast implants are still at risk of developing BIA-ALCL. While this risk is reportedly low, there are significant challenges, especially in the private sector, in obtaining a diagnosis.”
Moore highlighted the importance of early diagnosis in improving survival rates and outcomes. “Leigh Day continues to support women battling to obtain a BIA-ALCL diagnosis and appropriate treatment. Despite increased awareness of BIA-ALCL, it is concerning that some clinicians, particularly in the private sector, may not recognize the symptoms.”
Moore urged anyone diagnosed with BIA-ALCL who is considering legal action to contact the firm promptly. “We encourage those affected to reach out as soon as possible to explore their options for legal recourse.”
Related topics:
